Novavax Is Betting Its COVID Vaccine Will Win U.S. Authorization. Should You?

Novavax (NASDAQ: NVAX) can't market its COVID-19 vaccine in the United States. There's a simple reason why: The vaccine hasn't received U.S. Emergency Use Authorization (EUA) yet. However, that isn't stopping Novavax from launching a broader marketing campaign to increase awareness about its vaccine program.

These efforts indicate that Novavax is betting that its COVID-19 vaccine will win U.S. authorization. But should you?

Image source: Getty Images.

Continue reading

Source Fool.com